ストックスクリーナーアプリを入手
24.93
3.02%
0.73
アフターアワーズ：
25.29
0.36
+1.44%
前日終値:
$24.20
開ける：
$24.86
24時間の取引高:
1.12M
Relative Volume:
0.65
時価総額：
$3.98B
収益：
$1.27M
当期純損益:
$-508.02M
株価収益率:
-8.6541
EPS:
-2.8807
ネットキャッシュフロー:
$-419.23M
1週間 パフォーマンス:
+2.55%
1か月 パフォーマンス:
+7.88%
6か月 パフォーマンス:
+11.84%
1年 パフォーマンス:
+60.12%
1日の値動き範囲:
$24.81
$25.26
1週間の範囲:
$23.41
$25.70
52週間の値動き範囲:
$12.58
$27.30
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
24.93 | 3.99B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - AOL.com
145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC - MarketBeat
Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside - TipRanks
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? - TradingView
Edmond DE Rothschild Holding S.A. Invests $4.25 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali (DNLI) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Market Reaction: Shares Finish 3.25% UpDividend Increase Stocks - vinanet.vn
Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha
Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report - Sahm
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DNLI | US24823R1059 - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June R - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - Sahm
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - Yahoo Finance
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.com
Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingView
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41 - Moomoo
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds - Investing.com Nigeria
Denali Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking Alpha
DNLI SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Denali Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Denali Therapeutics Q2 Earnings Call Highlights - MarketBeat
Denali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Denali Q2 2026 earnings: AVLAYAH debuts with $3.6 million in revenue - TradingKey
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss - marketscreener.com
Denali Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q2 Revenue $3.6M, vs. FactSet Est of $2.2M - marketscreener.com
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics reports $3.6M in Q2 2026 product revenue, pro forma cash >$1.1B - TradingView
Denali Therapeutics Inc. 2026: Revenue $3.6M, EPS ($0.68) — 10-Q Summary - TradingView
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise - TradingView
Denali Therapeutics (NASDAQ: DNLI) posts Q2 loss and launches AVLAYAH - Stock Titan
BRIEF-Denali Therapeutics Q2 Operating Expenses USD 134.145 Million - TradingView
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
0.07%
1.21%
大文字化:
|
ボリューム (24 時間):